期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

卵巢癌早期诊断相关因子研究进展 被引量：5

暂未订购
导出
摘要 卵巢癌发病率在女性生殖系统恶性肿瘤中占第3位,但是病死率最高。卵巢癌早期一般没有特异性临床症状,70%~75%的卵巢癌确诊时已发展到晚期,5 a存活率低于30%,严重危害妇女健康。早期诊断并积极治疗可以明显改善卵巢癌患者的5 a生存率。多年来研究者一直进行研究并寻找简便高效的早期诊断指标。本文对卵巢癌早期相关的基因、蛋白、代谢产物,尤其对近年来研究较多的卵巢癌早期相关蛋白做一综述。
作者 图妮沙古丽.阿卜拉江 艾星子.艾里 丁岩
机构地区 新疆医科大学第一附属医院妇科
出处 《新乡医学院学报》 CAS 2013年第10期835-837,共3页 Journal of Xinxiang Medical University
关键词 卵巢癌 早期诊断 基因 蛋白 代谢产物
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献23

  • 1Li J,Dowdy S,Tipton T,et al. HE4 as a biomarker for ovarian and endometrial cancer management [ J ]. Expert Rev Mol Diagn, 2,009, 9(6) :555-566.
  • 2Behrens P, Rothe M, Florin A,et al. Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression[J]. Int J Mol Med,2001,8( 2 ) :149-154.
  • 3乐露露,傅芬.上皮性卵巢癌组织中EGFR、KRAS的表达变化及意义[J].山东医药,2011,51(46):16-18. 被引量：5
  • 4樊冬梅,何涛,周晓燕,谢晓娟,王焱.同一个体多种体液用于筛选卵巢癌早期诊断标志物的研究[J].医药论坛杂志,2012,33(1):58-59. 被引量：2
  • 5Goonewardene T I, Hall M R, Rustin G J. Management of asympto- matic patients on follow-up for ovarian cancer with rising CA125 concentrations [ J ]. Lancet 0ncol,2007,8 (9) : 813-$21.
  • 6Benjapibal M, Neungton C. Pre-operative prediction of serum CA125 level in women with ovarian masses [ J]. J Med Assoc Thai, 2007, 90(10) : 1986-1991.
  • 7栾晓蕊,李卫平,狄文.卵巢癌早期诊断的血清肿瘤标志物研究进展[J].国际妇产科学杂志,2009,36(6):458-461. 被引量：47
  • 8Andersen M R, Goff B A, Lowe K A, et al. Use of a Symptom In- dex, CA125 and HE4 to predict ovarian cancer[ J]. Gyneeol Oncol, 2010,116(3 ) :378-383.
  • 9Moore R G, McMeekin D S, Brown A K, et al . A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of o- varian cancer in patients with a pelvic mass [ J 1. Gynecol Oncol, 2009,112( 1 ) :40-46.
  • 10Moore R G, Brown A K, Miller M C, et al . The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass [ J ]. Gynecol Oncol, 2008,108 ( 2 ) : 402-408.

二级参考文献69

  • 1Maeda T, Inoue M, Koshiba S, et al. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125(MUC16) [J]. J Biol Chem, 2004, 279( 13): 13174-13182.
  • 2Benjapibal M, Neungton C. Pre-operative prediction of serumCA125 level in women with ovarian masses [J]. J Med Assoc Thai, 2007, 90( 10): 1986-1991.
  • 3Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer [J]. J Clin Oncol, 2005, 23 (31 ): 7919-7926.
  • 4Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass [J ]. Gynecol Oncol, 2008, 108 (2):402-408.
  • 5Zhang Z, Yu Y, Xu F, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer [J ]. Gynecol Oncol, 2007, 107(3): 526-531.
  • 6Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer [J]. Clin Cancer Res, 2008, 14 (4): 1065-1072.
  • 7Bertenshaw GP, Yip P, Seshaiah P, et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer [J]. Cancer Epidemiol Biomarkers Prey, 2008, 17(10): 2872-2881.
  • 8Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas [J]. Cancer Res, 2005, 65 (6): 2162-2169.
  • 9Ho M, Hassan R, Zhang J, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients [J]. Clin Cancer Res, 2005, 11 ( 10): 3814-3820.
  • 10Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer[J]. Clin Cancer Res, 2006, 12(2): 447-453.

共引文献84

同被引文献40

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量：1808
  • 2万崇华,方积乾,汤学良,张灿珍,卢玉波,孟琼,高丽.SF-36量表用于肝癌患者生活质量测定的效果评价[J].肿瘤,2005,25(5):492-494. 被引量：95
  • 3Liu S. Epigenetices advancing personalized nanomedicine in cancer therapy[ J]. Adv Drug Deliv Rev ,2012 ,64 ( 13 ) : 1532-1543.
  • 4Hagelkruys A, Sawicka A, Selser C, et al. The biology of HDAC in cancer: the nuclear and epigenetic components [ J ]. Handb Exp Pharmaco1,2011,206 :13-37.
  • 5Witt O, Deubzer H E, Milde T, et al. HDAC family : What are the cancer relevant targets [ J ]. Cancer Lett ,2009 ,277 ( 1 ) : 8-21.
  • 6Suzuki Y, Hasegawa M, Yamakawa M, et al. Radiosensitivity and radiation induced apoptosis:relationship to p53, p21 ( WAF-1 ) and Bb [ J ]. J Euro Radiat Oneol , 1997 ( Suppl 2 ) :81-85.
  • 7Carbone C, Melisi D. NF-κB as a target for pancreatic cancer thera- py[J]. Expert Opin Ther Targets,2012,16( Supple 2) :S1-S10.
  • 8钟军,熊戴群,罗辉,陈文学.肿瘤细胞放射敏感性与放射诱导凋亡关系的研究[J].实用癌症杂志,2007,22(6):560-564. 被引量：17
  • 9Yogurtcu B, Hatemi I, Aydin I, et al. NPRL2 gene expression in the progression of colon tumors [ J ]. Genet Mol Res, 2012, 11 ( 4 ) : 4810-4816.
  • 10Gao Y, Wang J, Fan G. NPRL2 is an independent prognostic factor of osteosarcoma [ J ]. Cancer Biomark,2013,12 ( 1 ) :31-36.

引证文献5

二级引证文献29

新乡医学院学报
2013年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部